RAB0745
Human TNFRSF17 ELISA Kit
Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
NACRES:
NA.32
UNSPSC Code:
41116158
Gene information:
human ... TNFRSF17(608)
Input:
sample type serum
sample type cell culture supernatant(s)
sample type plasma
sample type cell culture supernatant(s)
sample type plasma
Species reactivity:
human
Storage temp.:
−20°C
Shipped in:
wet ice
species reactivity
human
packaging
kit of 96 wells (12 strips x 8 wells)
technique(s)
ELISA: suitable
input
sample type serum
sample type cell culture supernatant(s)
sample type plasma
assay range
inter-assay cv: <12%
intra-assay cv: <10%
sensitivity: 48 pg/mL
standard curve range: 0.049-12 ng/mL
detection method
colorimetric
shipped in
wet ice
storage temp.
−20°C
Gene Information
human ... TNFRSF17(608)
General description
The antibody pair provided in this kit recognizes human Tumor Necrosis Factor Receptor Superfamily Member 17.
Application
For research use only. Not for use in diagnostic procedures.
Please refer to the attached General ELISA KIT Procedure (sandwich, competitive & Indirect ELISA)
Please refer to the attached General ELISA KIT Procedure (sandwich, competitive & Indirect ELISA)
signalword
Warning
hcodes
pcodes
Hazard Classifications
Met. Corr. 1
flash_point_f
Not applicable
flash_point_c
Not applicable
Storage Class
10 - Combustible liquids
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Related Content
Xun Ma et al.
Gene therapy, 26(5), 187-197 (2019-03-31)
Patients with immunoglobulin (Ig) light-chain (LC) diseases such as LC light-chain amyloidosis die with organ failure and need new therapies. We sought a model to test anti-LC siRNA delivery to human plasma cells, requiring circulating LC, in vivo indicators of
Javier Rodríguez-Carrio et al.
Frontiers in immunology, 9, 2351-2351 (2018-10-30)
Introduction: B-cell activation is pivotal in rheumatoid arthritis (RA) pathogenesis and represents a relevant therapeutic target. The main aim of this study was to characterize the profiles of B-cell factors and their decoy receptors in RA and evaluate their clinical
Vianihuini Figueroa-Vazquez et al.
Molecular cancer therapeutics, 20(2), 367-378 (2020-12-11)
Despite major treatment advances in recent years, patients with multiple myeloma inevitably relapse. The RNA polymerase II complex has been identified as a promising therapeutic target in both proliferating and dormant cancer cells. Alpha-amanitin, a toxin so far without clinical